, Volume 14, Issue 10, pp 1154–1164 | Cite as

TPCK-induced apoptosis and labelling of the largest subunit of RNA polymerase II in Jurkat cells

  • Z. Fabian
  • P. O’Brien
  • K. Pajęcka
  • H. O. Fearnhead
Original Paper


N-α-Tosyl-l-phenylalanyl chloromethyl ketone (TPCK) is an affinity label for chymotrypsin-like proteases and has been extensively used as an experimental tool in apoptosis research to probe the role of proteases in cell death. While TPCK blocks some apoptotic changes and induces others, the cellular target or targets for TPCK have not been identified. Here we investigated for the first time the cellular targets for TPCK using a polyclonal anti-tosyl antibody. We have found that TPCK rapidly and irreversibly labels numerous intracellular proteins and have identified one as RPB1, the largest subunit of RNA polymerase II. We show that TPCK inhibits DNA binding by RNA polymerase and that TPCK inhibits transcription. Inhibition of transcription is known to induce apoptosis and while TPCK may trigger death through interaction with multiple targets, our data suggests that the pro-apoptotic effects of TPCK may be explained in part by the inhibition of RNA polymerase II activity.


TPCK Anti-tosyl antibody DFF40 DFF35/45 RNA polymerase II RPB1 


  1. 1.
    Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C (2003) Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev 17:1487–1496PubMedCrossRefGoogle Scholar
  2. 2.
    Vande Walle L, Lamkanfi M, Vandenabeele P (2008) The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ 15:453–460CrossRefGoogle Scholar
  3. 3.
    Chowdhury D, Lieberman J (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26:389–420PubMedCrossRefGoogle Scholar
  4. 4.
    Wright SC, Wei QS, Zhong J, Zheng H, Kinder DH, Larrick JW (1994) Purification of a 24-kD protease from apoptotic tumor cells that activates DNA fragmentation. J Exp Med 180:2113–2123PubMedCrossRefGoogle Scholar
  5. 5.
    Bruno S, Del Bino G, Lassota P, Giaretti W, Darzynkiewicz Z (1992) Inhibitors of proteases prevent endonucleolysis accompanying apoptotic death of HL-60 leukemic cells and normal thymocytes. Leukemia 6:1113–1120PubMedGoogle Scholar
  6. 6.
    Fearnhead HO, Rivett AJ, Dinsdale D, Cohen GM (1995) A pre-existing protease is a common effector of thymocyte apoptosis mediated by diverse stimuli. FEBS Lett 357:242–246PubMedCrossRefGoogle Scholar
  7. 7.
    Hughes FM Jr, Evans-Storms RB, Cidlowski JA (1998) Evidence that non-caspase proteases are required for chromatin degradation during apoptosis. Cell Death Differ 5:1017–1027PubMedCrossRefGoogle Scholar
  8. 8.
    Murn J, Urleb U, Mlinaric-Rascan I (2004) Internucleosomal DNA cleavage in apoptotic WEHI 231 cells is mediated by a chymotrypsin-like protease. Genes Cells 9:1103–1111PubMedCrossRefGoogle Scholar
  9. 9.
    Schoellmann G, Shaw E (1962) A new method for labelling the active center of chymotrypsin. Biochem Biophys Res Commun 7:36–40PubMedCrossRefGoogle Scholar
  10. 10.
    Zhu H, Dinsdale D, Alnemri ES, Cohen GM (1997) Apoptosis in human monocytic THP.1 cells involves several distinct targets of N-tosyl-l-phenylalanyl chloromethyl ketone (TPCK). Cell Death Differ 4:590–599PubMedCrossRefGoogle Scholar
  11. 11.
    Huang Y, Sheikh MS, Fornace AJ Jr, Holbrook NJ (1999) Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene 18:3431–3439PubMedCrossRefGoogle Scholar
  12. 12.
    Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB (2004) Multiple effects of N-alpha-tosyl-l-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines. Cancer Biol Ther 3:761–768PubMedCrossRefGoogle Scholar
  13. 13.
    Kim K, Choi KH, Fu YM, Meadows GG, Joe CO (2003) Dephosphorylation of p53 during cell death by N-alpha-tosyl-l-phenylalanyl chloromethyl ketone. Biochem Biophys Res Commun 306:954–958PubMedCrossRefGoogle Scholar
  14. 14.
    Ballif BA, Shimamura A, Pae E, Blenis J (2001) Disruption of 3-phosphoinositide-dependent kinase 1 (PDK1) signaling by the anti-tumorigenic and anti-proliferative agent n-alpha-tosyl-l-phenylalanyl chloromethyl ketone. J Biol Chem 276:12466–12475PubMedCrossRefGoogle Scholar
  15. 15.
    Cromlish JA, Roeder RG (1989) Human transcription factor IIIC (TFIIIC). Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding. J Biol Chem 264:18100–18109PubMedGoogle Scholar
  16. 16.
    Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA (1993) Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 365:182–185PubMedCrossRefGoogle Scholar
  17. 17.
    Grammer TC, Blenis J (1996) The serine protease inhibitors, tosylphenylalanine chloromethyl ketone and tosyllysine chloromethyl ketone, potently inhibit pp70s6 k activation. J Biol Chem 271:23650–23652PubMedCrossRefGoogle Scholar
  18. 18.
    Chen Y (1999) Selective inhibition of ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease. Ann N Y Acad Sci 886:103–108PubMedCrossRefGoogle Scholar
  19. 19.
    Pasternack MS, Sitkovsky MV, Eisen HN (1983) The site of action of N-alpha-tosyl-l-lysyl-chloromethyl-ketone (TLCK) on cloned cytotoxic T lymphocytes. J Immunol 131:2477–2483PubMedGoogle Scholar
  20. 20.
    Harlow E, Lane D (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp 100–120Google Scholar
  21. 21.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRefGoogle Scholar
  22. 22.
    Ryan KM, Vousden KH (1998) Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18:3692–3698PubMedGoogle Scholar
  23. 23.
    Fung LW, Ho C, Roth EF Jr, Nagel RL (1975) The alkylation of hemoglobin S by nitrogen mustard. High resolution proton nuclear magnetic resonance studies. J Biol Chem 250:4786–4789PubMedGoogle Scholar
  24. 24.
    Price CC, Gaucher GM, Koneru P, Shibakawa R, Sowa JR, Yamaguchi M (1968) Relative reactivities for monofunctional nitrogen mustard alkylation of nucleic acid components. Biochim Biophys Acta 166:327–359PubMedGoogle Scholar
  25. 25.
    Bhatia U, Danishefsky K, Traganos F, Darzynkiewicz Z (1995) Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard. Clin Cancer Res 1:873–880PubMedGoogle Scholar
  26. 26.
    O’Connor PM, Wassermann K, Sarang M, Magrath I, Bohr VA, Kohn KW (1991) Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt’s lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 51:6550–6557PubMedGoogle Scholar
  27. 27.
    Wolf BB, Schuler M, Echeverri F, Green DR (1999) Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 274:30651–30656PubMedCrossRefGoogle Scholar
  28. 28.
    Jeong JY, Kim KU, Jue DM (1997) Tosylphenylalanine chloromethyl ketone inhibits TNF-alpha mRNA synthesis in the presence of activated NF-kappa B in RAW 264.7 macrophages. Immunology 92:267–273PubMedCrossRefGoogle Scholar
  29. 29.
    Mbikay M, Garrick MD (1981) Inhibition of initiation of protein synthesis by tosyl-l-lysyl chloromethyl ketone. Can J Biochem 59:321–327PubMedCrossRefGoogle Scholar
  30. 30.
    Vidali G, Karn J, Allfrey VG (1975) Selective effects of inhibitors of protein synthesis on metabolism of nuclear and cytoplasmic proteins: evidence for coordinate synthesis of non-histone chromosomal proteins. Proc Natl Acad Sci USA 72:4450–4454PubMedCrossRefGoogle Scholar
  31. 31.
    Martin SJ, Lennon SV, Bonham AM, Cotter TG (1990) Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 145:1859–1867PubMedGoogle Scholar
  32. 32.
    Young FS, Neidhardt FC (1978) Effect of inhibitors of elongation factor Tu on the metabolic regulation of protein synthesis in Escherichia coli. J Bacteriol 135:675–686PubMedGoogle Scholar
  33. 33.
    Chapman RD, Heidemann M, Albert TK et al (2007) Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7. Science 318:1780–1782PubMedCrossRefGoogle Scholar
  34. 34.
    Matthews BW, Sigler PB, Henderson R, Blow DM (1967) Three-dimensional structure of tosyl-alpha-chymotrypsin. Nature 214:652–656PubMedCrossRefGoogle Scholar
  35. 35.
    Hara S, Halicka HD, Bruno S, Gong J, Traganos F, Darzynkiewicz Z (1996) Effect of protease inhibitors on early events of apoptosis. Exp Cell Res 223:372–384PubMedCrossRefGoogle Scholar
  36. 36.
    Jonak J, Rychlik I (1973) Study of conditions for the inhibitory effect of N-tosyl-l-phenylalanylchloromethane on protein synthesis and the possibility of existence of different forms of the elongation factor S3 in Bacillus stearothermophilus. Biochim Biophys Acta 324:554–562PubMedGoogle Scholar
  37. 37.
    Peter ME, Brockmoller J, Jonak J, Sprinzl M (1989) Identification of the N-tosyl-l-phenylalanyl chloromethylketone modification site in Thermus thermophilus elongation factor Tu. FEBS Lett 257:219–222PubMedCrossRefGoogle Scholar
  38. 38.
    Phatnani HP, Greenleaf AL (2006) Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev 20:2922–2936PubMedCrossRefGoogle Scholar
  39. 39.
    Kim MK, Nikodem VM (1999) hnRNP U inhibits carboxy-terminal domain phosphorylation by TFIIH and represses RNA polymerase II elongation. Mol Cell Biol 19:6833–6844PubMedGoogle Scholar
  40. 40.
    Du L, Warren SL (1997) A functional interaction between the carboxy-terminal domain of RNA polymerase II and pre-mRNA splicing. J Cell Biol 136:5–18PubMedCrossRefGoogle Scholar
  41. 41.
    McCracken S, Fong N, Rosonina E et al (1997) 5’-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II. Genes Dev 11:3306–3318PubMedCrossRefGoogle Scholar
  42. 42.
    Meinhart A, Cramer P (2004) Recognition of RNA polymerase II carboxy-terminal domain by 3’-RNA-processing factors. Nature 430:223–226PubMedCrossRefGoogle Scholar
  43. 43.
    Custodio N, Vivo M, Antoniou M, Carmo-Fonseca M (2007) Splicing- and cleavage-independent requirement of RNA polymerase II CTD for mRNA release from the transcription site. J Cell Biol 179:199–207PubMedCrossRefGoogle Scholar
  44. 44.
    Jeong SJ, Kim HJ, Yang YJ et al (2005) Role of RNA polymerase II carboxy terminal domain phosphorylation in DNA damage response. J Microbiol 43:516–522PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Z. Fabian
    • 1
    • 2
  • P. O’Brien
    • 1
  • K. Pajęcka
    • 3
  • H. O. Fearnhead
    • 1
  1. 1.Pharmacology and TherapeuticsSchool of Medicine and National Centre for Biomedical Engineering Science, School of Science, Room 213, Orbsen BuildingGalwayIreland
  2. 2.Department of Medical BiologyUniversity of PécsPecsHungary
  3. 3.Science Foundation Ireland Undergraduate Research Experience and Knowledge Award ProgrammeDublinIreland

Personalised recommendations